DISCOUNT-ZERTIFIKAT - ROCHE GS Share Price

Certificat

DE000KH8E2Y2

Market Closed - Deutsche Boerse AG 18:30:39 10/05/2024 BST
229.5 EUR +0.65% Intraday chart for DISCOUNT-ZERTIFIKAT - ROCHE GS
Current month+2.31%
1 month+1.05%
Date Price Change Volume
10/05/24 229.5 +0.65% 0
09/05/24 228 +0.37% 0
08/05/24 227.2 +0.60% 0
07/05/24 225.8 +1.04% 0
06/05/24 223.5 +0.52% 0

Delayed Quote Deutsche Boerse AG

Last update May 10, 2024 at 06:30 pm

More quotes

Static data

Product typeDiscount Certificates
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Citi Citi
WKN KH8E2Y
ISINDE000KH8E2Y2
Date issued 27/07/2023
Maturity 20/06/2024 (39 Days)
Parity 1 : 1
Emission price 241.3
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 248.5
Lowest since issue 218.8

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
225.1 CHF
Average target price
279.4 CHF
Spread / Average Target
+24.12%
Consensus